Utidelone has been selected twice for oral presentations at the ASCO annual meeting and approved in 2021 for the treatment of mBC.
Utidelone has been selected twice for oral presentations at the ASCO annual meeting and approved in 2021 for the treatment of mBC.
Building balanced and differentiated pipeline covering products from early- to late-stage through both in-house development and in-licensing.
We are actively selecting partners through in/out- licensing and co-development to build differentiated pipeline and to achieve win-win situation.
What does innovative anti-cancer drug development mean to patients, investigators and Biostar, respectively?